Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of Alzheimer’s disease (Alzheimer’s), bipolar disorder, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company’s pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). The Company’s AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.